CD274 and neoplasm: The mechanisms underlying BCG response have been investigated in addition to gene expression patterns and the tumor microenvironment, and these studies showed that patients who do not respond to BCG treatment exhibit elevated levels of PD-L1 expression in their tumors compared to those who respond to BCG therapy [62], implying that the tumor microenvironment before treatment is a critical determinant of the BCG response mechanism [8].